Prevalence of Multidisciplinary Pelvic Symptoms at Intake of Patients with Chronic Pelvic Pain to a Single Academic Institution.

Patel S1, Gaba F2, Denis T2, Mekonnen M1, Feustel P3, De E4

Research Type

Clinical

Abstract Category

Pelvic Pain Syndromes

Abstract 483
Open Discussion ePosters
Scientific Open Discussion Session 102
Wednesday 23rd October 2024
13:15 - 13:20 (ePoster Station 6)
Exhibition Hall
Pain, other Pain, Pelvic/Perineal Quality of Life (QoL) Sexual Dysfunction Prolapse Symptoms
1. Albany Medical College, 43 New Scotland Avenue, Albany, NY, 2. Department of Urology, Albany Medical Center, 23 Hackett Blvd, Albany, NY, 3. Department of Neuroscience and Experimental Therapeutics, Albany Medical College, 43 New Scotland Avenue, Albany, NY, 4. Professor of Urology, Obstetrics and Gynecology, Neurology Director, Multidisciplinary Pelvic Health, Albany Medical Center Albany Medical College, Albany New York Department of Urology, Albany Medical Center, 23 Hackett Blvd, Albany, NY
Presenter
Links

Poster

Abstract

Hypothesis / aims of study
Chronic pelvic pain (CPP) is a complex condition of heterogeneous etiology. We hypothesize, in our single-center retrospective cohort of comprehensive electronic patient intake forms, that patients with pelvic pain will show a strong prevalence of sexual, urinary, gastrointestinal, psychological, and neurological symptomatology.
Study design, materials and methods
259 patients completed the electronic intake for our subspecialized adult Urogynecology and Reconstructive Pelvic Surgery (URPS) clinic. Of the 259 patients 114 reported “yes” to pelvic pain, and 138 reported “no”, the remaining 7 patients did not answer the survey. 38 (14.7%) were male, 215 (83%) female, and 6 (2.3%) identified as transgender. Statistical analysis included unpaired t-tests. Validated measures were: POPDI-6, autonomic symptom score, PHQ4 (anxiety and depression), UDI-6 (urinary symptoms), neuro-urological symptoms, PISQIR (sexual health and function), CRAD-8 (lower urinary tract symptoms, GUPI pain subscales/total and quality of life scores (genitourinary pain), AUASS (urinary symptoms) and SHIM (sexual health inventory).
Results
The results are attached as a table below.
Interpretation of results
Patients with pelvic pain reported significantly higher POPDI-6 scores (mean 39.4 ± 21.5 vs. 23.1 ± 18.3, respectively, t value -5.3, p value <0.001), autonomic symptoms (mean 6.7 ± 6.2 vs. 3.4 ± 3.5, respectively, t value = -4.1, p value < 0.001), PHQ-4 scores (mean 3.5 ± 3.3 vs. 1.8 ± 2.8, respectively, t value = -4.4, p value <0.001) compared to those without pelvic pain, higher urinary UDI-6 scores (mean 50.4 ± 24.9 vs. 40.1 ± 23.4, respectively, p value = 0.009, t value = -2.7), significantly more neuro-urological symptoms (mean 3.5 ± 2.7 vs. 1.6 ± 2.2, respectively, p value < 0.001, t value = -6.1) PISQR scores (mean 3.2 ± 0.7 vs. 3.6 ± 0.6, respectively, t value = -2.3, p value = 0.03), significantly higher CRAD-8 scores (mean 27.4 ± 20.7 vs. 21.0 ± 20.0, respectively, t value = -2.2, p value = 0.03), GUPI pain subscale scores (mean 12.8 ± 4.9 vs. 0.8, ± 1.1, respectively, t value = -24.5, p value <0.001) compared to those without pelvic pain, higher GUPI quality of life scores (mean 8.9 ± 2.9 vs. 3.9 ± 1.7, t value = -16.3, p value <0.001 and higher GUPI total scores (mean 4.7 ± 1.3 vs. 4.0 ± 1.6, respectively, t value = – 3.9, p value <0.001). Pelvic pain was not associated with AUASS and SHIM. (Table 1)
Concluding message
Our findings suggest a significant association between pelvic pain and sexual, urinary, bowel, pelvic, psychological, neurological and autonomic symptoms. A multidisciplinary approach is recommended when managing CPP in order to achieve optimal quality of life.
Figure 1 Table 1: Pelvic pain was associated with POPDI-6, autonomic symptom score, PHQ4, UDI-6, neuro-urological symptoms, PISQIR, CRAD-8, GUPI pain subscales/total and quality of life scores, but not AUASS and SHIM.
Disclosures
Funding Grants: Underactive Bladder (NIDDK) Clinical Research: PI, Ironwood Pharmaceuticals Consultant: Flume catheters, Luca Biologics. Infinite MD / Consumer Medical/ Alight Online 2nd Opinion Advisory Board: Ironwood Pharmaceuticals Glycologix Other: National Institute of Diabetes and Digestive and Kidney Diseases, PsyD ClinicalTrials.gov ID: NCT05127616 Protocol Number: EPPIC22001, version 1.0 Date of Charter: July 13, 2022 – Chair, DSMB* Clinical Trial No Subjects Human Ethics Committee Albany Medical College Institutional Review Board Helsinki Yes Informed Consent Yes
13/11/2024 22:36:46